Anzeige
Mehr »
Montag, 30.06.2025 - Börsentäglich über 12.000 News
Diese KI-Biotech-Aktie revolutioniert die Krebstherapie: Lernen Sie Rakovina Therapeutics kennen
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3C9E5 | ISIN: US00444A1016 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
ACCUSTEM SCIENCES INC Chart 1 Jahr
5-Tage-Chart
ACCUSTEM SCIENCES INC 5-Tage-Chart

Aktuelle News zur ACCUSTEM SCIENCES Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
16.06.AccuStem Sciences, Inc. Announces Chairman Purchase of Shares167LONDON and PHOENIX, June 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced...
► Artikel lesen
13.06.AccuStem Sciences Chairman Gabriele Cerrone buys additional 8,991 shares2
13.06.AccuStem Sciences, Inc. Announces Chairman Purchase of Shares166LONDON, June 13, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced that its Chairman...
► Artikel lesen
20.05.Accustem Sciences Inc. - 10-Q, Quarterly Report1
ACCUSTEM SCIENCES Aktie jetzt für 0€ handeln
28.04.AccuStem Sciences, Inc. and EmeritusDX Announce Partnership to Commercialize MSC Test for Lung Cancer Screening301LONDON and PHOENIX, Ariz., April 28, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk...
► Artikel lesen
21.04.AccuStem Sciences reports share purchase by Chairman3
21.04.AccuStem Sciences, Inc. Announces Chairman Purchase of Shares185LONDON and PHOENIX, Ariz., April 21, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced...
► Artikel lesen
16.04.AccuStem Sciences, Inc. Signs Agreement to Access Blood Samples from Lung Cancer Screening Trial to Expedite MSC Commercialization Plan268LONDON and PHOENIX, April 16, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer...
► Artikel lesen
10.04.AccuStem Sciences, Inc. Announces Chairman Purchase of Shares224LONDON and PHOENIX, April 10, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced...
► Artikel lesen
08.04.AccuStem Sciences, Inc. Announces Chairman Purchase of Shares1
04.04.AccuStem Sciences, Inc.: AccuStem Sciences to Offer its MSC Blood Test to Lung Cancer Screening Programs in the United States332LONDON and PHOENIX, April 04, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with or at risk of cancer...
► Artikel lesen
03.04.Accustem Sciences Inc. - 10-K, Annual Report2
18.03.AccuStem Sciences, Inc. Announces Acquisition of Proprietary MSC Lung Cancer Screening Test252AccuStem pursuing strategic commercialization plan intending to launch the MSC test in the US in 2026 LONDON and PHOENIX, Ariz., March 18, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB:...
► Artikel lesen
03.01.AccuStem Sciences announces chairman purchase of shares6
03.01.AccuStem Sciences, Inc. Announces Chairman Purchase of Shares317LONDON and PHOENIX, Jan. 03, 2025 (GLOBE NEWSWIRE) -- AccuStem Sciences, Inc. (OTCQB: ACUT), a clinical stage diagnostics company dedicated to improving outcomes for patients with cancer, announced...
► Artikel lesen
15 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1